Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Kidney Injury | 56 | 2024 | 1925 | 9.670 |
Why?
|
Fibroblast Growth Factors | 14 | 2020 | 867 | 3.170 |
Why?
|
Critical Illness | 30 | 2023 | 2722 | 2.220 |
Why?
|
Renal Replacement Therapy | 12 | 2023 | 281 | 1.940 |
Why?
|
Cardiac Surgical Procedures | 12 | 2021 | 3629 | 1.520 |
Why?
|
Intensive Care Units | 23 | 2022 | 3742 | 1.340 |
Why?
|
Iron | 7 | 2023 | 1787 | 1.310 |
Why?
|
Kidney | 15 | 2024 | 7046 | 0.970 |
Why?
|
Cisplatin | 4 | 2024 | 1647 | 0.970 |
Why?
|
Kidney Calculi | 3 | 2013 | 463 | 0.870 |
Why?
|
Platelet Factor 4 | 1 | 2023 | 129 | 0.870 |
Why?
|
Anemia, Hemolytic, Autoimmune | 3 | 2021 | 147 | 0.870 |
Why?
|
Vitamins | 4 | 2022 | 1635 | 0.860 |
Why?
|
Calcitriol | 2 | 2014 | 296 | 0.850 |
Why?
|
Nephritis, Interstitial | 3 | 2022 | 155 | 0.830 |
Why?
|
Hospital Mortality | 21 | 2022 | 5283 | 0.830 |
Why?
|
Vitamin D | 10 | 2021 | 3303 | 0.790 |
Why?
|
Ritonavir | 1 | 2023 | 329 | 0.750 |
Why?
|
Diphenhydramine | 1 | 2021 | 63 | 0.740 |
Why?
|
Dialysis Solutions | 1 | 2020 | 33 | 0.700 |
Why?
|
Renal Insufficiency, Chronic | 8 | 2023 | 2241 | 0.690 |
Why?
|
Hemoglobins | 4 | 2019 | 1524 | 0.680 |
Why?
|
Critical Care | 7 | 2021 | 2697 | 0.670 |
Why?
|
Cardiopulmonary Bypass | 4 | 2020 | 1094 | 0.650 |
Why?
|
Creatinine | 8 | 2024 | 1898 | 0.650 |
Why?
|
Peritoneal Dialysis | 1 | 2020 | 159 | 0.640 |
Why?
|
Hyperkalemia | 2 | 2023 | 233 | 0.630 |
Why?
|
Iron Chelating Agents | 1 | 2019 | 141 | 0.620 |
Why?
|
Thrombotic Microangiopathies | 2 | 2018 | 123 | 0.620 |
Why?
|
Sepsis | 4 | 2020 | 2583 | 0.600 |
Why?
|
ABO Blood-Group System | 1 | 2020 | 380 | 0.590 |
Why?
|
Kidney Diseases | 2 | 2024 | 2093 | 0.590 |
Why?
|
Hypocalcemia | 1 | 2019 | 199 | 0.570 |
Why?
|
Glucuronidase | 1 | 2019 | 202 | 0.570 |
Why?
|
Minerals | 1 | 2019 | 284 | 0.570 |
Why?
|
Mesothelioma | 1 | 2023 | 807 | 0.570 |
Why?
|
Hyperphosphatemia | 2 | 2019 | 38 | 0.560 |
Why?
|
Humans | 128 | 2024 | 760437 | 0.560 |
Why?
|
Cation Exchange Resins | 1 | 2016 | 19 | 0.550 |
Why?
|
Causality | 1 | 2022 | 1243 | 0.540 |
Why?
|
Glomerular Filtration Rate | 8 | 2024 | 2171 | 0.530 |
Why?
|
Polystyrenes | 1 | 2016 | 104 | 0.530 |
Why?
|
Vitamin D Deficiency | 2 | 2019 | 1384 | 0.520 |
Why?
|
Cholecalciferol | 1 | 2021 | 552 | 0.520 |
Why?
|
Antimicrobial Cationic Peptides | 2 | 2015 | 353 | 0.520 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1163 | 0.510 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2024 | 2008 | 0.510 |
Why?
|
Kidney Glomerulus | 2 | 2020 | 567 | 0.450 |
Why?
|
Heme Oxygenase-1 | 1 | 2016 | 365 | 0.450 |
Why?
|
Organ Transplantation | 2 | 2021 | 1154 | 0.450 |
Why?
|
24,25-Dihydroxyvitamin D 3 | 1 | 2013 | 8 | 0.440 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2021 | 989 | 0.440 |
Why?
|
Middle Aged | 62 | 2024 | 220382 | 0.430 |
Why?
|
Osteomalacia | 1 | 2013 | 60 | 0.420 |
Why?
|
Aged | 55 | 2024 | 168840 | 0.420 |
Why?
|
Fluorobenzenes | 1 | 2014 | 179 | 0.410 |
Why?
|
Unnecessary Procedures | 1 | 2016 | 415 | 0.400 |
Why?
|
Hydrocephalus, Normal Pressure | 1 | 2013 | 100 | 0.400 |
Why?
|
Lateral Ventricles | 1 | 2013 | 146 | 0.400 |
Why?
|
Parathyroid Hormone | 6 | 2019 | 1802 | 0.400 |
Why?
|
Vitamin D-Binding Protein | 1 | 2013 | 131 | 0.400 |
Why?
|
Postoperative Complications | 6 | 2020 | 15627 | 0.400 |
Why?
|
Female | 75 | 2024 | 391875 | 0.380 |
Why?
|
Laxatives | 1 | 2012 | 92 | 0.380 |
Why?
|
Ergocalciferols | 1 | 2012 | 110 | 0.370 |
Why?
|
Male | 73 | 2024 | 360035 | 0.370 |
Why?
|
Kidney Function Tests | 4 | 2020 | 675 | 0.370 |
Why?
|
Hypercalciuria | 1 | 2010 | 31 | 0.370 |
Why?
|
Cefoxitin | 1 | 2010 | 35 | 0.370 |
Why?
|
Kidney Transplantation | 3 | 2021 | 4226 | 0.370 |
Why?
|
Medical Order Entry Systems | 1 | 2016 | 521 | 0.360 |
Why?
|
Cerebral Ventricles | 1 | 2013 | 542 | 0.360 |
Why?
|
Nephrolithiasis | 1 | 2012 | 115 | 0.360 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5663 | 0.350 |
Why?
|
Drug Monitoring | 1 | 2016 | 961 | 0.340 |
Why?
|
Neoplasms | 5 | 2024 | 22083 | 0.340 |
Why?
|
Nurse-Patient Relations | 1 | 2010 | 100 | 0.340 |
Why?
|
Anemia, Hemolytic | 1 | 2010 | 163 | 0.330 |
Why?
|
Facility Design and Construction | 1 | 2010 | 86 | 0.330 |
Why?
|
Urokinase-Type Plasminogen Activator | 2 | 2020 | 325 | 0.320 |
Why?
|
Rhabdomyolysis | 1 | 2009 | 152 | 0.310 |
Why?
|
Respiratory Insufficiency | 3 | 2021 | 1230 | 0.310 |
Why?
|
Sinoatrial Node | 1 | 2008 | 99 | 0.310 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6475 | 0.300 |
Why?
|
Immunotherapy | 3 | 2021 | 4649 | 0.300 |
Why?
|
Immunologic Factors | 2 | 2017 | 1588 | 0.300 |
Why?
|
Standard of Care | 2 | 2021 | 550 | 0.290 |
Why?
|
Risk Factors | 22 | 2024 | 74055 | 0.290 |
Why?
|
Research Design | 1 | 2022 | 6168 | 0.280 |
Why?
|
Pregnancy Complications | 1 | 2021 | 2946 | 0.270 |
Why?
|
Connexins | 1 | 2008 | 352 | 0.270 |
Why?
|
Hydrocephalus | 1 | 2013 | 764 | 0.270 |
Why?
|
Acetazolamide | 1 | 2006 | 96 | 0.270 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2006 | 91 | 0.270 |
Why?
|
Altitude Sickness | 1 | 2006 | 91 | 0.260 |
Why?
|
Cystatin C | 2 | 2024 | 270 | 0.260 |
Why?
|
Adult | 38 | 2024 | 220781 | 0.260 |
Why?
|
Polymorphism, Genetic | 1 | 2016 | 4287 | 0.250 |
Why?
|
Cathelicidins | 2 | 2015 | 80 | 0.240 |
Why?
|
Cohort Studies | 19 | 2024 | 41366 | 0.240 |
Why?
|
Sulfonamides | 1 | 2014 | 1973 | 0.240 |
Why?
|
Retrospective Studies | 22 | 2024 | 80430 | 0.230 |
Why?
|
Risk Assessment | 5 | 2024 | 23953 | 0.230 |
Why?
|
Anemia, Iron-Deficiency | 2 | 2019 | 369 | 0.230 |
Why?
|
Brain Diseases | 1 | 2013 | 1544 | 0.230 |
Why?
|
Ferritins | 2 | 2019 | 597 | 0.230 |
Why?
|
Renal Dialysis | 4 | 2023 | 1795 | 0.230 |
Why?
|
Prone Position | 2 | 2021 | 196 | 0.220 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 2 | 2020 | 75 | 0.220 |
Why?
|
Calcium | 2 | 2017 | 5726 | 0.220 |
Why?
|
Clinical Trials as Topic | 2 | 2016 | 7996 | 0.210 |
Why?
|
Receptors, Interleukin-6 | 2 | 2021 | 225 | 0.210 |
Why?
|
Incidence | 9 | 2021 | 21322 | 0.200 |
Why?
|
Hemochromatosis | 1 | 2023 | 174 | 0.200 |
Why?
|
Oxygen | 2 | 2021 | 4222 | 0.200 |
Why?
|
Pyrimidines | 1 | 2014 | 3024 | 0.200 |
Why?
|
Transferrin | 2 | 2023 | 284 | 0.200 |
Why?
|
Phosphates | 3 | 2016 | 770 | 0.200 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2021 | 422 | 0.200 |
Why?
|
Educational Measurement | 1 | 2009 | 1250 | 0.200 |
Why?
|
Bradycardia | 1 | 2023 | 299 | 0.190 |
Why?
|
Bilirubin | 1 | 2023 | 437 | 0.190 |
Why?
|
Patient Positioning | 2 | 2021 | 326 | 0.190 |
Why?
|
Prospective Studies | 11 | 2020 | 54339 | 0.190 |
Why?
|
Kidney Tubules | 2 | 2020 | 449 | 0.190 |
Why?
|
Iron Overload | 1 | 2023 | 239 | 0.190 |
Why?
|
Kidney Failure, Chronic | 2 | 2017 | 2462 | 0.190 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13616 | 0.190 |
Why?
|
Pandemics | 7 | 2022 | 8623 | 0.190 |
Why?
|
Colonic Neoplasms | 1 | 2013 | 2529 | 0.180 |
Why?
|
Heart Arrest | 2 | 2021 | 1502 | 0.180 |
Why?
|
Treatment Outcome | 11 | 2023 | 64591 | 0.180 |
Why?
|
Program Evaluation | 1 | 2009 | 2493 | 0.180 |
Why?
|
United States | 19 | 2022 | 72202 | 0.180 |
Why?
|
Immunotherapy, Adoptive | 2 | 2020 | 1463 | 0.180 |
Why?
|
Antibodies, Monoclonal | 2 | 2020 | 9176 | 0.180 |
Why?
|
Dexamethasone | 2 | 2020 | 1944 | 0.180 |
Why?
|
Glycerophosphates | 1 | 2020 | 47 | 0.180 |
Why?
|
Antiviral Agents | 2 | 2023 | 3066 | 0.170 |
Why?
|
Iatrogenic Disease | 1 | 2023 | 538 | 0.170 |
Why?
|
Oxygen Consumption | 1 | 2006 | 1859 | 0.170 |
Why?
|
Medical Futility | 1 | 2021 | 136 | 0.170 |
Why?
|
Magnesium | 1 | 2023 | 809 | 0.170 |
Why?
|
Hemorrhage | 3 | 2021 | 3414 | 0.170 |
Why?
|
Education, Medical, Undergraduate | 1 | 2009 | 1066 | 0.170 |
Why?
|
Retroperitoneal Space | 1 | 2020 | 170 | 0.170 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 3243 | 0.170 |
Why?
|
Aged, 80 and over | 13 | 2021 | 58859 | 0.170 |
Why?
|
Prednisone | 2 | 2017 | 1564 | 0.160 |
Why?
|
Severity of Illness Index | 7 | 2021 | 15820 | 0.160 |
Why?
|
Intraoperative Care | 2 | 2021 | 766 | 0.160 |
Why?
|
Resuscitation Orders | 1 | 2021 | 270 | 0.160 |
Why?
|
Sarcopenia | 1 | 2024 | 372 | 0.160 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 109 | 0.160 |
Why?
|
Anemia | 1 | 2008 | 1508 | 0.160 |
Why?
|
Sodium | 2 | 2016 | 1589 | 0.160 |
Why?
|
Length of Stay | 5 | 2021 | 6413 | 0.160 |
Why?
|
Renin-Angiotensin System | 1 | 2023 | 737 | 0.150 |
Why?
|
Arrhythmias, Cardiac | 1 | 2008 | 2248 | 0.150 |
Why?
|
Health Care Rationing | 1 | 2021 | 437 | 0.150 |
Why?
|
Glucocorticoids | 2 | 2019 | 2163 | 0.150 |
Why?
|
Comorbidity | 6 | 2021 | 10494 | 0.150 |
Why?
|
Biosynthetic Pathways | 1 | 2018 | 135 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 10180 | 0.150 |
Why?
|
Vomiting | 1 | 2021 | 652 | 0.150 |
Why?
|
Hospitals | 2 | 2021 | 3873 | 0.150 |
Why?
|
Blood Coagulation Disorders | 1 | 2021 | 350 | 0.150 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2021 | 410 | 0.140 |
Why?
|
Salivary Proteins and Peptides | 1 | 2017 | 48 | 0.140 |
Why?
|
Interferon Regulatory Factor-2 | 1 | 2017 | 22 | 0.140 |
Why?
|
Comparative Effectiveness Research | 1 | 2022 | 708 | 0.140 |
Why?
|
Students, Dental | 1 | 2019 | 173 | 0.140 |
Why?
|
Patients | 1 | 2024 | 905 | 0.140 |
Why?
|
Hyperparathyroidism | 1 | 2019 | 337 | 0.140 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2020 | 335 | 0.140 |
Why?
|
Pilot Projects | 3 | 2023 | 8611 | 0.140 |
Why?
|
Natural Killer T-Cells | 1 | 2020 | 311 | 0.140 |
Why?
|
Thrombosis | 2 | 2021 | 2940 | 0.140 |
Why?
|
Internet | 1 | 2009 | 3092 | 0.140 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 1031 | 0.130 |
Why?
|
Blood Protein Electrophoresis | 1 | 2016 | 71 | 0.130 |
Why?
|
Heparin | 1 | 2023 | 1633 | 0.130 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1517 | 0.130 |
Why?
|
Cryoglobulins | 1 | 2016 | 58 | 0.130 |
Why?
|
Arteriosclerosis | 1 | 2020 | 1055 | 0.130 |
Why?
|
Respiration, Artificial | 3 | 2023 | 2622 | 0.130 |
Why?
|
Prognosis | 5 | 2021 | 29551 | 0.130 |
Why?
|
Hepatitis E | 1 | 2017 | 76 | 0.130 |
Why?
|
Glomerulonephritis, Membranous | 1 | 2017 | 88 | 0.130 |
Why?
|
Transplantation Conditioning | 2 | 2023 | 1588 | 0.130 |
Why?
|
Antibodies | 1 | 2023 | 2421 | 0.130 |
Why?
|
Substance-Related Disorders | 1 | 2012 | 4416 | 0.130 |
Why?
|
Myocardium | 1 | 2008 | 4700 | 0.130 |
Why?
|
Nephrectomy | 1 | 2020 | 934 | 0.120 |
Why?
|
Complement C4 | 1 | 2016 | 244 | 0.120 |
Why?
|
Adenocarcinoma | 1 | 2013 | 6330 | 0.120 |
Why?
|
Pleural Neoplasms | 1 | 2020 | 609 | 0.120 |
Why?
|
Fibrosis | 2 | 2020 | 2048 | 0.120 |
Why?
|
Logistic Models | 4 | 2020 | 13240 | 0.120 |
Why?
|
Multivariate Analysis | 3 | 2013 | 12054 | 0.120 |
Why?
|
Apolipoproteins | 1 | 2017 | 325 | 0.120 |
Why?
|
Erythropoietin | 1 | 2019 | 719 | 0.120 |
Why?
|
Triage | 1 | 2021 | 986 | 0.120 |
Why?
|
Erythrocyte Transfusion | 2 | 2021 | 565 | 0.120 |
Why?
|
NAD | 1 | 2018 | 614 | 0.120 |
Why?
|
Urine | 1 | 2016 | 362 | 0.120 |
Why?
|
T-Box Domain Proteins | 1 | 2017 | 468 | 0.120 |
Why?
|
Kidney Neoplasms | 2 | 2021 | 4241 | 0.120 |
Why?
|
Blood Coagulation | 1 | 2020 | 1154 | 0.120 |
Why?
|
Acid-Base Equilibrium | 1 | 2015 | 181 | 0.110 |
Why?
|
Adiposity | 1 | 2024 | 1870 | 0.110 |
Why?
|
Biopsy | 2 | 2016 | 6765 | 0.110 |
Why?
|
Lipocalins | 1 | 2015 | 161 | 0.110 |
Why?
|
Hospital Design and Construction | 1 | 2014 | 33 | 0.110 |
Why?
|
Complement C3 | 1 | 2016 | 451 | 0.110 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2016 | 288 | 0.110 |
Why?
|
Patients' Rooms | 1 | 2014 | 61 | 0.110 |
Why?
|
Acute-Phase Proteins | 1 | 2015 | 250 | 0.110 |
Why?
|
Urinalysis | 1 | 2016 | 368 | 0.110 |
Why?
|
Urea | 1 | 2016 | 444 | 0.110 |
Why?
|
Erythropoiesis | 1 | 2017 | 682 | 0.110 |
Why?
|
APACHE | 2 | 2014 | 267 | 0.110 |
Why?
|
Blood Loss, Surgical | 1 | 2017 | 636 | 0.110 |
Why?
|
Survival Rate | 5 | 2021 | 12698 | 0.110 |
Why?
|
Proteinuria | 1 | 2016 | 600 | 0.110 |
Why?
|
Time Factors | 6 | 2017 | 39947 | 0.100 |
Why?
|
Catalysis | 1 | 2014 | 774 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3080 | 0.100 |
Why?
|
Animals | 12 | 2020 | 168253 | 0.100 |
Why?
|
Algorithms | 3 | 2021 | 14002 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3200 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2017 | 675 | 0.100 |
Why?
|
Hypophosphatemia | 1 | 2013 | 92 | 0.100 |
Why?
|
Injections, Intravenous | 1 | 2014 | 1379 | 0.100 |
Why?
|
Anti-Bacterial Agents | 1 | 2010 | 7424 | 0.100 |
Why?
|
Hospitalization | 6 | 2023 | 10698 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3157 | 0.100 |
Why?
|
Cell Count | 1 | 2016 | 1834 | 0.100 |
Why?
|
Autoantibodies | 2 | 2021 | 2123 | 0.100 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2020 | 2531 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 2 | 2015 | 4509 | 0.090 |
Why?
|
Paraneoplastic Syndromes | 1 | 2013 | 155 | 0.090 |
Why?
|
Case-Control Studies | 5 | 2017 | 22097 | 0.090 |
Why?
|
Immune Tolerance | 1 | 2020 | 2300 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2058 | 0.090 |
Why?
|
Cyclophosphamide | 1 | 2017 | 2218 | 0.090 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2202 | 0.090 |
Why?
|
Eosinophils | 1 | 2016 | 947 | 0.090 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2852 | 0.090 |
Why?
|
Menorrhagia | 1 | 2010 | 59 | 0.090 |
Why?
|
Signal Transduction | 3 | 2020 | 23397 | 0.090 |
Why?
|
Graft vs Host Disease | 1 | 2023 | 3028 | 0.090 |
Why?
|
Drug Utilization | 1 | 2016 | 1188 | 0.090 |
Why?
|
Patient Selection | 2 | 2019 | 4240 | 0.090 |
Why?
|
25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2009 | 58 | 0.090 |
Why?
|
Postoperative Period | 1 | 2015 | 1807 | 0.090 |
Why?
|
New York City | 1 | 2012 | 730 | 0.080 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1405 | 0.080 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2021 | 1460 | 0.080 |
Why?
|
Diagnostic Tests, Routine | 1 | 2015 | 786 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 2 | 2021 | 3159 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 2 | 2017 | 1807 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2204 | 0.080 |
Why?
|
Odds Ratio | 3 | 2020 | 9639 | 0.080 |
Why?
|
Disease Management | 2 | 2016 | 2501 | 0.080 |
Why?
|
Population Surveillance | 1 | 2019 | 2603 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39078 | 0.080 |
Why?
|
Hospitals, General | 1 | 2013 | 798 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 3 | 2022 | 1874 | 0.080 |
Why?
|
Anticoagulants | 2 | 2021 | 4806 | 0.080 |
Why?
|
Glomerulonephritis | 1 | 2010 | 336 | 0.080 |
Why?
|
Coronary Angiography | 1 | 2020 | 4468 | 0.080 |
Why?
|
Cerebral Hemorrhage | 1 | 2019 | 2656 | 0.070 |
Why?
|
Microscopy, Video | 1 | 2008 | 242 | 0.070 |
Why?
|
Shock, Septic | 1 | 2014 | 764 | 0.070 |
Why?
|
Sex Factors | 1 | 2021 | 10538 | 0.070 |
Why?
|
Ventilators, Mechanical | 1 | 2010 | 288 | 0.070 |
Why?
|
ras Proteins | 1 | 2013 | 1052 | 0.070 |
Why?
|
Connexin 43 | 1 | 2008 | 200 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7380 | 0.070 |
Why?
|
Checklist | 1 | 2014 | 827 | 0.070 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2011 | 495 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3610 | 0.070 |
Why?
|
Medical Staff, Hospital | 1 | 2011 | 601 | 0.070 |
Why?
|
Quality of Life | 1 | 2008 | 13338 | 0.070 |
Why?
|
New York | 1 | 2009 | 872 | 0.070 |
Why?
|
Microscopy, Fluorescence | 2 | 2017 | 2647 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2191 | 0.070 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4849 | 0.070 |
Why?
|
Students, Medical | 1 | 2019 | 1930 | 0.070 |
Why?
|
Age of Onset | 1 | 2013 | 3302 | 0.070 |
Why?
|
Leiomyoma | 1 | 2010 | 636 | 0.060 |
Why?
|
Reference Values | 1 | 2013 | 4921 | 0.060 |
Why?
|
Hematinics | 1 | 2008 | 282 | 0.060 |
Why?
|
Adolescent | 6 | 2021 | 88196 | 0.060 |
Why?
|
Resuscitation | 1 | 2010 | 661 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4020 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2021 | 12320 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1741 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15257 | 0.060 |
Why?
|
Atrial Appendage | 1 | 2008 | 283 | 0.060 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2008 | 866 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2014 | 2215 | 0.060 |
Why?
|
Blood Transfusion | 1 | 2010 | 1299 | 0.060 |
Why?
|
Mice, Knockout | 3 | 2020 | 14397 | 0.060 |
Why?
|
Stroke Volume | 1 | 2017 | 5487 | 0.050 |
Why?
|
Up-Regulation | 1 | 2012 | 4116 | 0.050 |
Why?
|
Veterans | 1 | 2017 | 2642 | 0.050 |
Why?
|
Massachusetts | 1 | 2016 | 8826 | 0.050 |
Why?
|
Disease Models, Animal | 3 | 2020 | 18216 | 0.050 |
Why?
|
Baclofen | 1 | 2023 | 120 | 0.050 |
Why?
|
Ultrasonography | 1 | 2016 | 5966 | 0.050 |
Why?
|
Digoxin | 1 | 2023 | 246 | 0.050 |
Why?
|
Immunity, Innate | 1 | 2014 | 3059 | 0.050 |
Why?
|
Linear Models | 1 | 2012 | 5865 | 0.050 |
Why?
|
Boston | 1 | 2015 | 9326 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7849 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10746 | 0.050 |
Why?
|
Mice | 7 | 2020 | 81402 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5815 | 0.050 |
Why?
|
Quality Improvement | 1 | 2016 | 3798 | 0.050 |
Why?
|
Young Adult | 5 | 2021 | 59068 | 0.050 |
Why?
|
Action Potentials | 1 | 2008 | 1830 | 0.050 |
Why?
|
Kinetics | 1 | 2008 | 6377 | 0.040 |
Why?
|
Consensus | 1 | 2010 | 3115 | 0.040 |
Why?
|
Sclerosis | 1 | 2020 | 210 | 0.040 |
Why?
|
Vancomycin | 1 | 2023 | 503 | 0.040 |
Why?
|
Receptors, Lysophosphatidic Acid | 1 | 2020 | 77 | 0.040 |
Why?
|
Receptors, Chemokine | 1 | 2023 | 653 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12429 | 0.040 |
Why?
|
Adaptation, Physiological | 1 | 2006 | 1301 | 0.040 |
Why?
|
Antigens, CD1d | 1 | 2020 | 217 | 0.040 |
Why?
|
Cytokines | 1 | 2014 | 7377 | 0.040 |
Why?
|
Mycophenolic Acid | 1 | 2021 | 347 | 0.040 |
Why?
|
Candida | 1 | 2020 | 173 | 0.040 |
Why?
|
Time | 1 | 2021 | 544 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 12918 | 0.040 |
Why?
|
Pentosyltransferases | 1 | 2018 | 62 | 0.040 |
Why?
|
Pregnancy | 1 | 2021 | 29831 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 325 | 0.040 |
Why?
|
Quinolinic Acid | 1 | 2018 | 67 | 0.040 |
Why?
|
Prevalence | 2 | 2019 | 15698 | 0.040 |
Why?
|
Mortality | 2 | 2021 | 2897 | 0.040 |
Why?
|
Thrombophilia | 1 | 2021 | 305 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2021 | 859 | 0.040 |
Why?
|
Troponin I | 1 | 2022 | 635 | 0.040 |
Why?
|
Age Factors | 2 | 2020 | 18379 | 0.040 |
Why?
|
Liposarcoma | 1 | 2020 | 285 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13312 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12969 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2010 | 3405 | 0.040 |
Why?
|
Primary Health Care | 1 | 2014 | 4674 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2024 | 20551 | 0.040 |
Why?
|
Platelet Count | 1 | 2020 | 780 | 0.040 |
Why?
|
Candidiasis | 1 | 2020 | 364 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12653 | 0.040 |
Why?
|
Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2017 | 67 | 0.040 |
Why?
|
Survival Analysis | 2 | 2021 | 10075 | 0.030 |
Why?
|
Medical Records, Problem-Oriented | 1 | 2016 | 35 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15476 | 0.030 |
Why?
|
Leiomyosarcoma | 1 | 2020 | 422 | 0.030 |
Why?
|
Parotid Gland | 1 | 2017 | 175 | 0.030 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 416 | 0.030 |
Why?
|
Tryptophan | 1 | 2018 | 482 | 0.030 |
Why?
|
Niacinamide | 1 | 2018 | 413 | 0.030 |
Why?
|
Podocytes | 1 | 2020 | 406 | 0.030 |
Why?
|
Aftercare | 1 | 2021 | 911 | 0.030 |
Why?
|
Atrophy | 1 | 2020 | 1631 | 0.030 |
Why?
|
Heart | 1 | 2008 | 4391 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 17854 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2326 | 0.030 |
Why?
|
Electrocardiography | 1 | 2008 | 6380 | 0.030 |
Why?
|
Proton Pump Inhibitors | 1 | 2019 | 530 | 0.030 |
Why?
|
Netherlands | 1 | 2019 | 2218 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2020 | 779 | 0.030 |
Why?
|
Protein Folding | 1 | 2017 | 867 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2020 | 1110 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2008 | 12785 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2021 | 1409 | 0.030 |
Why?
|
Heart Failure | 1 | 2017 | 11653 | 0.030 |
Why?
|
Saliva | 1 | 2017 | 827 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14565 | 0.030 |
Why?
|
United States Department of Veterans Affairs | 1 | 2017 | 923 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 26063 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2017 | 2569 | 0.020 |
Why?
|
Drug Combinations | 1 | 2017 | 2043 | 0.020 |
Why?
|
Reperfusion Injury | 1 | 2017 | 1023 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2017 | 1112 | 0.020 |
Why?
|
Cause of Death | 1 | 2021 | 3686 | 0.020 |
Why?
|
HIV Infections | 1 | 2017 | 17328 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2013 | 1759 | 0.020 |
Why?
|
Metabolomics | 1 | 2020 | 1653 | 0.020 |
Why?
|
Disease Progression | 2 | 2017 | 13484 | 0.020 |
Why?
|
Ischemia | 1 | 2018 | 1876 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4549 | 0.020 |
Why?
|
Outpatients | 1 | 2017 | 1596 | 0.020 |
Why?
|
Aging | 1 | 2008 | 8689 | 0.020 |
Why?
|
Administration, Oral | 1 | 2017 | 4010 | 0.020 |
Why?
|
Physician Assistants | 1 | 2011 | 190 | 0.020 |
Why?
|
Patient Discharge | 1 | 2021 | 3436 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3822 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8522 | 0.020 |
Why?
|
Data Collection | 1 | 2017 | 3321 | 0.020 |
Why?
|
Viral Load | 1 | 2017 | 3329 | 0.020 |
Why?
|
Nurse Practitioners | 1 | 2011 | 270 | 0.020 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1863 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9533 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2017 | 22121 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6297 | 0.020 |
Why?
|
Homeostasis | 1 | 2017 | 3320 | 0.020 |
Why?
|
Folic Acid | 1 | 2013 | 1315 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7230 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5778 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15598 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10759 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2017 | 4168 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6230 | 0.010 |
Why?
|
Proteomics | 1 | 2017 | 3818 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5491 | 0.010 |
Why?
|
Genotype | 1 | 2017 | 12976 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11729 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9410 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2017 | 4518 | 0.010 |
Why?
|
Models, Biological | 1 | 2017 | 9462 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 12932 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 11900 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 15867 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2015 | 20078 | 0.010 |
Why?
|
Internship and Residency | 1 | 2011 | 5866 | 0.010 |
Why?
|